Theo Schetters studied Biology at Utrecht University in the Netherlands.  In 1980 he was employed at the Department of Immunology of the Veterinary Faculty of the University of Utrecht where he worked on the antigenic diversity of Trypanosoma parasites. From 1981 to 1987 he worked at the Department of Cytology and Histology at the University of Nijmegen in the Netherlands where he studied immune responsiveness of mice against Plasmodium berghei infection. In 1986 he obtained a PhD in Medicine from Nijmegen University in the Netherlands, and received a visiting scientist award from the Royal Society (London) to work on malaria immunology at the National Institute for Medical Research in Mill Hill, London (UK). From 1988 to 2014 he worked at Intervet International (Boxmeer, The Netherlands) where he developed a vaccine against coccidiosis in chickens (Nobilis® Cox ATM) and a vaccine against Babesia infections in dogs (Nobivac® Piro). He is inventor of recombinant vaccines against Babesia divergens and Babesia canis, and an improved vaccine formulation against Rhipicephalus ticks. Presently, he is director of ProtActivity, a company that focuses on vaccine development against ticks and tick-borne protozoal infections, and coordinator of CATVAC a consortium that works on the development of a vaccine against Rhipicephalus microplus ticks. He holds an Extraordinary Professor position at the Department of Veterinary Tropical Diseases, University of Pretoria, Pretoria, South Africa.